# Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

> **NCT05239741** · PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 100 (estimated)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** 5-fluorouracil
- **DRUG:** Irinotecan
- **BIOLOGICAL:** Bevacizumab
- **BIOLOGICAL:** Cetuximab

## Key facts

- **NCT ID:** NCT05239741
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-02
- **Primary completion:** 2028-09-19
- **Final completion:** 2028-09-19
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05239741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05239741, "Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05239741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*